MAKO Surgical Corp. Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Over-Allotment Option

FORT LAUDERDALE, Fla., Aug 19, 2009 (GlobeNewswire via COMTEX News Network) — MAKO Surgical Corp. (Nasdaq:MAKO), a medical device company that markets both its RIO(r) Robotic Arm Interactive Orthopedic surgical platform and proprietary RESTORIS(r) implants for minimally invasive orthopedic knee procedures known as MAKOplasty(r), today announced that it has closed its public offering of 8,050,000 shares of its common stock, which includes 1,050,000 shares issued as a result of the underwriters’ exercise of their over-allotment option. Piper Jaffray & Co. acted as the sole book-running manager for the offering and Leerink Swann LLC acted as co-manager.

MAKO plans to use the net proceeds of approximately $54.4 million, after deducting underwriting discounts and commissions and estimated expenses of the offering, to support commercialization, sales, marketing and general administrative activities, for research and product development activities and to fund working capital and other general corporate purposes.

The offering was made only by means of a prospectus and related prospectus supplement, copies of which may be obtained by contacting Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924. Electronic copies of the prospectus and the prospectus supplement are available on the Securities and Exchange Commission’s website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state.

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button